MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer

Xie, Minhao; Fu, Ziyi; Cao, Jianxiang; Liu, Yuan; Wu, Jie; Li, Qing; Chen, Yun

doi:10.1016/j.biopha.2018.03.088

Cited by 55 publications

(25 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Target gene expression is regulated by two mechanisms: (i) binding to the untranslated region (3'UTR) of the target messenger RNA (mRNA) 3' end, inhibiting its translation; and (ii) like small interfering RNA (siRNA), miRNA binds to the target and degrades target mRNA . Recent studies have found that miRNAs regulate drug resistance by mediating their targeting genes in various cancers . In recent years, abnormal expression of miR‐873 has been found in many kinds of tumors, such as breast and ovarian cancers, and glioma .…”

Section: Introductionmentioning

confidence: 99%

“…[17][18][19] Recent studies have found that miRNAs regulate drug resistance by mediating their targeting genes in various cancers. [20][21][22][23][24] In recent years, abnormal expression of miR-873 has been found in many kinds of tumors, such as breast and ovarian cancers, and glioma. [25][26][27] MiR-873 plays a role in promoting cancer or anticancer by regulating tumor cell invasion, migration, proliferation, apoptosis, and sensitivity to chemotherapeutic drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

Jin

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe five‐year survival rate of non‐small cell lung cancer (NSCLC) patients is very low. MiR‐873 is involved in the growth, metastasis, and differentiation of tumors. Herein, we determined the target gene and influence of miR‐873 in NSCLC.MethodsMiRanda and Targetscan websites were used to predict the target gene of miR‐873 in NSCLC. Luciferase activity was examined using a dual luciferase reporter gene assay kit. The viability, tube formation, and proliferation of cells were analyzed by cell counting kit‐8, angiogenic analysis, and flow cytometry, respectively. The levels of miR‐873 and GLI1 were evaluated using quantitative real‐time PCR and Western blot assays.ResultsLow levels of GLI1 and high levels of miR‐873 were observed in an NSCLC cell line (PC9) highly sensitive to EGFR‐tyrosine kinase inhibitors. There was a negative correlation between miR‐873 and GLI1 expression in PC9 and PC9/GR cells. The inhibition of miR‐873 enhanced GLI1 levels. MiR‐873 expression was inhibited by gefitinib. Gefitinib markedly reduced the viability, tube formation, and cell number in PC9 cells. However, suppression of miR‐873 enhanced the resistance and knockdown of GLI1 enhanced the sensitivity of PC9 cells to gefitinib.Conclusions GLI1 is a target gene of miR‐873 in NSCLC. The inhibition of miR‐873 increased gefitinib resistance of NSCLC cells via the upregulation of GLI1. These results indicate that miR‐873‐GLI1 signaling is involved in gefitinib resistance in NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

Jin

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…For example, miR-132 level was obviously lower in human bladder cancer and overexpression of miR-132 inhibited cell proliferation and invasion to some extent [31]. miR-132 overexpression notably reduced cell proliferation and colony formation, and promoted cell apoptosis in breast cancer cells [32]. In our study, miR-132 was downregulated in OSCC tissues and OSCC cells, miR-132 overexpression inhibited cell proliferation, migration, and invasion, and accelerated apoptosis in OSCC, suggesting that miR-132 is the tumor suppressor.…”

Section: Discussionmentioning

confidence: 99%

MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1

Chen

Zhu

et al. 2020

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Recently, miR‐212 was found or proposed to participate in the regulation of cancer sensitivity to chemotherapy or radiotherapy. Xie et al found that miR‐132/‐212‐3p may induce drug resistance of in breast cancer via the miR‐132/‐212‐3p/PTEN/AKT/NF‐κB/BCRP pathway. Further, they suggested that it could improve the treatment effects of doxorubicin, and they identified novel therapeutic targets for breast cancer by modulating miR‐132/‐212‐3p.…”

Section: The Role Of Mir‐212 In Cancermentioning

confidence: 99%

“…Recently, miR-212 was found or proposed to participate in the regulation of cancer sensitivity to chemotherapy or radiotherapy. Xie et al59 found that…”

mentioning

confidence: 99%

The functions and targets of miR‐212 as a potential biomarker of cancer diagnosis and therapy

Song

Bian

Yang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Cancer is a major health problem worldwide. An increasing number of researchers are studying the diagnosis, therapy and mechanisms underlying the development and progression of cancer. The study of noncoding RNA has attracted a lot of attention in recent years. It was found that frequent alterations of miRNA expression not only have various functions in cancer but also that miRNAs can act as clinical markers of diagnosis, stage and progression of cancer. MiR‐212 is an important example of miRNAs involved in cancer. According to recent studies, miR‐212 may serve as an oncogene or tumour suppressor by influencing different targets or pathways during the oncogenesis and the development and metastasis of cancer. Its deregulation may serve as a marker for the diagnosis or prognosis of cancer. In addition, it was recently reported that miR‐212 was related to the sensitivity or resistance of cancer cells to chemotherapy or radiotherapy. Here, we summarize the current understanding of miR‐212 functions in cancer by describing the relevant signalling pathways and targets. The role of miR‐212 as a biomarker and its therapeutic potential in cancer is also described. The aim of this review was to identify new methods for the diagnosis and treatment of human cancers.

show abstract

MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer

Cited by 55 publications

References 39 publications

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1

The functions and targets of miR‐212 as a potential biomarker of cancer diagnosis and therapy

Contact Info

Product

Resources

About